Novo Nordisk A/S (NYSE:NVO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Novo Nordisk A/S (NYSE:NVO) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $145.67.

Several equities research analysts recently weighed in on NVO shares. BMO Capital Markets reissued an “outperform” rating and set a $163.00 price objective on shares of Novo Nordisk A/S in a report on Tuesday. The Goldman Sachs Group started coverage on Novo Nordisk A/S in a report on Thursday, May 30th. They set a “buy” rating and a $156.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Monday, June 17th. Finally, Argus raised their price objective on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Cravens & Co Advisors LLC raised its position in shares of Novo Nordisk A/S by 1.0% in the 1st quarter. Cravens & Co Advisors LLC now owns 8,250 shares of the company’s stock worth $1,059,000 after acquiring an additional 85 shares in the last quarter. Sage Rhino Capital LLC increased its position in Novo Nordisk A/S by 0.7% in the 1st quarter. Sage Rhino Capital LLC now owns 12,320 shares of the company’s stock valued at $1,582,000 after buying an additional 89 shares in the last quarter. U.S. Capital Wealth Advisors LLC increased its position in Novo Nordisk A/S by 0.6% in the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company’s stock valued at $1,595,000 after buying an additional 90 shares in the last quarter. Essex LLC increased its position in Novo Nordisk A/S by 2.0% in the 1st quarter. Essex LLC now owns 4,684 shares of the company’s stock valued at $601,000 after buying an additional 90 shares in the last quarter. Finally, JCIC Asset Management Inc. increased its position in Novo Nordisk A/S by 0.3% in the 1st quarter. JCIC Asset Management Inc. now owns 27,552 shares of the company’s stock valued at $3,538,000 after buying an additional 90 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 1.2 %

Shares of NVO opened at $142.81 on Friday. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $148.15. The business’s fifty day moving average is $135.00 and its 200-day moving average is $123.35. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. The firm has a market cap of $640.86 billion, a price-to-earnings ratio of 49.24, a PEG ratio of 1.43 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The company had revenue of $9.52 billion for the quarter, compared to the consensus estimate of $9.23 billion. Equities analysts anticipate that Novo Nordisk A/S will post 3.41 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.